Potential for an Innovative New HIV Treatment to Become the Preferred Therapy
Annandale, VA; June 26, 2023
Gilead Sciences, Inc. has been a global leader in developing HIV/AIDS therapies for over 3 decades. The leaders and researchers of the Clinical Alliance for Research and Education-Infectious Diseases (CARE-ID) are proud to have collaborated with Gilead over the years for many of its developments. We are now partnering with Gilead again in pursuing what could be a truly monumental innovation in HIV treatment. This new clinical trial has just gotten started, and we are extremely excited to welcome our first study participants into the screening process.
Optimizing outcomes and reducing the laborious regimens of care for people living with HIV has been a goal for as long as HIV therapies have been offered. One key to achieving this goal has been developing longer acting options for patients. Lenacapavir (LEN) is a Gilead innovation with the potential to be a preferred and versatile foundational long-acting agent due to its therapeutic potency and a range of dosing frequencies and administration options.
Gilead HIV Clinical Development vice-president Jared Baeten said, “We’re excited to share promising Phase Ib clinical trial results that reinforce lenacapavir’s potential to be a foundational agent for long-acting combination HIV treatment options, and we are especially pleased to see the potential of the combination of lenacapavir plus bNAbs dosed once every six months. We are committed to exploring novel therapy approaches that may help deliver care for all people living with HIV, with a focus on developing person-centric options that fit into the diverse lives of people living with the virus, as we continue in our pursuit of ending the HIV epidemic for everyone, everywhere.”
CARE-ID yearslong focus on HIV research will take another step forward with this new clinical trial.